{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T11:56:22Z","timestamp":1793793382832,"version":"4.6.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15964-z","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T04:51:48Z","timestamp":1756702308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A disproportionality analysis of real-world adverse events associated with tirofiban from the FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Qian","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungang","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"15964_CR1","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1016\/j.jtha.2023.09.013","volume":"21","author":"L Stanger","year":"2023","unstructured":"Stanger, L., Yamaguchi, A. & Holinstat, M. Antiplatelet strategies: Past, present, and future. J. Thromb. Haemost. JTH 21, 3317\u20133328 (2023).","journal-title":"J. Thromb. Haemost. JTH"},{"key":"15964_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40292-023-00562-9","volume":"30","author":"J Sharifi-Rad","year":"2023","unstructured":"Sharifi-Rad, J. et al. An updated review on glycoprotein IIb\/IIIa inhibitors as antiplatelet agents: Basic and clinical perspectives. High Blood Press Cardiovasc. Prev. 30, 93\u2013107 (2023).","journal-title":"High Blood Press Cardiovasc. Prev."},{"key":"15964_CR3","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-0037-1616241","volume":"86","author":"BS Coller","year":"2001","unstructured":"Coller, B. S. Anti-GPIIb\/IIIa drugs: Current strategies and future directions. Thromb. Haemost. 86, 427\u2013443 (2001).","journal-title":"Thromb. Haemost."},{"key":"15964_CR4","doi-asserted-by":"crossref","unstructured":"Huynh, T., Theroux, P., Snapinn, S., Wan, Y., & Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca. Effect of platelet glycoprotein IIb\/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina\/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Am. Heart J.  146, 668\u2013673.","DOI":"10.1016\/S0002-8703(03)00255-2"},{"issue":"2176","key":"15964_CR5","first-page":"2190","volume":"360","author":"RP Giugliano","year":"2009","unstructured":"Giugliano, R. P. et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N. Engl. J. Med. 360(2176), 2190 (2009).","journal-title":"N. Engl. J. Med."},{"key":"15964_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.110.958041","volume":"123","author":"TY Wang","year":"2011","unstructured":"Wang, T. Y. et al. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: An analysis from the early glycoprotein IIb\/IIIa inhibition in patients with non-st-segment elevation acute coronary syndrome (EARLY ACS) trial. Circulation 123, 722\u2013730 (2011).","journal-title":"Circulation"},{"key":"15964_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa031859","volume":"350","author":"A Kastrati","year":"2004","unstructured":"Kastrati, A. et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 350, 232\u2013238 (2004).","journal-title":"N. Engl. J. Med."},{"key":"15964_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jamainternmed.2016.0166","volume":"176","author":"X Zheng","year":"2016","unstructured":"Zheng, X. et al. Coronary catheterization and percutaneous coronary intervention in China: 10-year results from China PEACE-Retrospective cathpci study. JAMA Intern. Med. 176, 512\u2013521 (2016).","journal-title":"JAMA Intern. Med."},{"key":"15964_CR9","doi-asserted-by":"publisher","first-page":"e042229","DOI":"10.1136\/bmjopen-2020-042229","volume":"10","author":"AS Lam","year":"2020","unstructured":"Lam, A. S., Yan, B. P. & Lee, V. W. Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study. BMJ Open 10, e042229 (2020).","journal-title":"BMJ Open"},{"key":"15964_CR10","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne, R. A. et al. ESC Guidelines for the management of acute coronary syndromes. Eur. Heart J. 44, 3720\u20133826 (2023).","journal-title":"Eur. Heart J."},{"key":"15964_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/eurheartj\/ehp376","volume":"31","author":"M Valgimigli","year":"2010","unstructured":"Valgimigli, M. et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials.. Eur Heart J. 31, 35\u201349 (2010).","journal-title":"Eur Heart J."},{"key":"15964_CR12","unstructured":"RESCUE BT Trial Investigators et al. Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: The RESCUE BT randomized clinical trial. JAMA 328, 543\u2013553 (2022)."},{"key":"15964_CR13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1001\/jamaneurol.2024.0868","volume":"81","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: A randomized clinical trial. JAMA Neurol. 81, 594\u2013602 (2024).","journal-title":"JAMA Neurol."},{"key":"15964_CR14","first-page":"515","volume":"79","author":"M Yang","year":"2019","unstructured":"Yang, M., Huo, X., Miao, Z. & Wang, Y. Platelet glycoprotein IIb\/IIIa receptor inhibitor tirofiban in acute ischemic stroke. Drugs 79, 515\u2013529 (2019).","journal-title":"Drugs"},{"key":"15964_CR15","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1161\/STROKEAHA.110.599662","volume":"42","author":"M Siebler","year":"2011","unstructured":"Siebler, M. et al. Safety of tirofiban in acute ischemic stroke: The SaTIS trial. Stroke 42, 2388\u20132392 (2011).","journal-title":"Stroke"},{"key":"15964_CR16","doi-asserted-by":"publisher","first-page":"2233425","DOI":"10.1080\/07853890.2023.2233425","volume":"55","author":"J Wang","year":"2023","unstructured":"Wang, J. & Zou, D. Tirofiban-induced thrombocytopenia. Ann. Med. 55, 2233425 (2023).","journal-title":"Ann. Med."},{"key":"15964_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.3390\/jcm9072212","volume":"9","author":"C Vayne","year":"2020","unstructured":"Vayne, C. et al. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J. Clin. Med. 9, 2212 (2020).","journal-title":"J. Clin. Med."},{"key":"15964_CR18","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1161\/01.CIR.99.22.2892","volume":"99","author":"MW McClure","year":"1999","unstructured":"McClure, M. W. et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome the platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 99, 2892\u20132900 (1999).","journal-title":"Circulation"},{"key":"15964_CR19","first-page":"e48","volume":"2","author":"E \u0130lhan","year":"2010","unstructured":"\u0130lhan, E. et al. A fatal complication of tirofiban in an octogenarian: Diffuse alveolar hemorrhage. J. Cardiol. Cases 2, e48\u2013e51 (2010).","journal-title":"J. Cardiol. Cases"},{"key":"15964_CR20","first-page":"149","volume":"24","author":"M Conley","year":"2008","unstructured":"Conley, M. et al. Abciximab-induced alveolar hemorrhage after percutaneous coronary intervention can. J. Cardiol. 24, 149\u2013151 (2008).","journal-title":"J. Cardiol."},{"issue":"93","key":"15964_CR21","first-page":"94","volume":"206","author":"X Zhou","year":"2016","unstructured":"Zhou, X. et al. Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia. Int J. Cardiol. 206(93), 94 (2016).","journal-title":"Int J. Cardiol."},{"issue":"186","key":"15964_CR22","first-page":"188","volume":"15","author":"A Ali","year":"2003","unstructured":"Ali, A. et al. Use of platelet glycoprotein IIb\/IIIa inhibitors and spontaneous pulmonary hemorrhage. J. Invasive Cardiol. 15(186), 188 (2003).","journal-title":"J. Invasive Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15964-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15964-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:14:12Z","timestamp":1760444052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15964-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15964"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15964-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: In this article Qian Guo, Xiang Li, and Chuanliang Zhao should have been denoted as equally contributing authors.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32043"}}